Overexpression of phosphoserine aminotransferase 1 (PSAT1) predicts poor prognosis and associates with tumor progression in human esophageal squamous cell carcinoma
Contact your GP if you experience persistent palpitations, frequent dizziness or lightheadedness, fainting episodes, chest pain, unusual shortness of breath, or symptoms that worsen progressively rather than improving after dose stabilisation
Lab Monitoring : For patients with liver disease, regular monitoring of liver enzymes (ALT, AST) and other markers helps track progress and adjust treatment
DIRECTIONS OF USE: Take one shot (25ml) 30-45 minutes before breakfast or before workout
7.2 Methodological constraints Methodological limitations are evident: animal models (e.g., CUMS, DSS colitis) differ from human diseases, and microbiota transplantation studies remain largely restricted to murine models